Open Payments

California Pacific Medical Center

Type
Teaching hospital
Where
San Francisco, CA
Medicare CCN
050047
Received
$913,618 in 113 records, 2023 ($7,357 general, $906,261 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment6$7,357
2023Research payment107$906,261

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC12$527,6682023
Genentech, Inc.15$216,0502023
PTC Therapeutics, Inc.6$40,6872023
Amylyx Pharmaceuticals, Inc.1$28,7982023
ModernaTX, Inc.6$28,1002023
Boston Scientific Corporation16$25,5902023
Medtronic, Inc.8$17,0742023
Regeneron Pharmaceuticals, Inc.8$13,4662023
CSL Behring33$7,8242023
Jenavalve Technology, Inc.1$4,9862023
Sterilmed, Inc.3$1,4632023
Medline Industries LP2$9072023
F. Hoffmann-La Roche AG1$5002023
Amgen Inc.1$5002023

By nature of payment

NatureRecordsAmount
Research payment107$906,261
Compensation for services other than consulting, including serving as faculty or as a speaker at a v4$6,449
Debt forgiveness2$907

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31Merck Sharp & Dohme LLC$263,518Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2023
2023-12-31Merck Sharp & Dohme LLC$135,048Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with 2023
2023-12-31Merck Sharp & Dohme LLC$55,638Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2023
2023-12-31Merck Sharp & Dohme LLC$23,372Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP2023
2023-12-31Merck Sharp & Dohme LLC$19,030Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2023
2023-12-31Merck Sharp & Dohme LLC$2,887Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2023
2023-12-31Medline Industries LP$659Debt forgivenessCash or cash equivalent2023
2023-12-31Merck Sharp & Dohme LLC$543Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2023
2023-12-31Medline Industries LP$248Debt forgivenessCash or cash equivalent2023
2023-12-31Merck Sharp & Dohme LLC$41Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician s C2023
2023-12-31Merck Sharp & Dohme LLC$4Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab MK3475 in newly diagnosed and2023
2023-12-31Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto2023
2023-12-12F. Hoffmann-La Roche AG$500Research paymentCash or cash equivalentCotellic Drug, BioOncologyPh 1b study of cobimetinib and PARP inhibitor with or without atezolizumab in PSOC2023
2023-12-11Medtronic, Inc.$10,500Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsEMBOLISE2023
2023-12-08CSL Behring$243Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-12-05PTC Therapeutics, Inc.$13,733Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2023
2023-12-05PTC Therapeutics, Inc.$5,380Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2023
2023-11-20Boston Scientific Corporation$6,396Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-11-20Boston Scientific Corporation$500Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-11-20CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-11-17CSL Behring$5,989Research paymentCash or cash equivalentA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-11-17CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-11-17CSL Behring$18Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-11-08ModernaTX, Inc.$14,908Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2023
2023-11-08ModernaTX, Inc.$4,009Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2023
2023-11-02Genentech, Inc.$750Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-10-19CSL Behring$108Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-10-19CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-10-19CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-10-19CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-10-19CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-10-19CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-10-19CSL Behring$18Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-10-04Genentech, Inc.$21,655Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-09-25Merck Sharp & Dohme LLC$20,446Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2023
2023-09-19Boston Scientific Corporation$1,374Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023
2023-09-18Boston Scientific Corporation$1,248Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-08-21Boston Scientific Corporation$274Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-08-17Genentech, Inc.$1,550Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-08-16Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-08-14CSL Behring$90Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-08-14CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-08-11ModernaTX, Inc.$5,346Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2023
2023-08-04Genentech, Inc.$28,068Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-08-03PTC Therapeutics, Inc.$18,104Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2023
2023-08-03Jenavalve Technology, Inc.$4,986Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments)Cash or cash equivalentJenaValve Pericardial TAVR System Device, Cardiology2023
2023-07-26Boston Scientific Corporation$3,878Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-07-04PTC Therapeutics, Inc.$1,469Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2023
2023-06-22Genentech, Inc.$71,738Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-06-20Regeneron Pharmaceuticals, Inc.$1,268Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-06-14CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-06-14CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-06-14CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-06-14CSL Behring$36Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-06-07ModernaTX, Inc.$1,336Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2023
2023-06-01Boston Scientific Corporation$1,104Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023
2023-05-30Regeneron Pharmaceuticals, Inc.$1,119Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-05-25Genentech, Inc.$6,898Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-05-23Genentech, Inc.$16,620Research paymentCash or cash equivalentPhase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients2023
2023-05-22Boston Scientific Corporation$1,221Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-05-01Boston Scientific Corporation$2,208Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023
2023-04-28Amgen Inc.$500Research paymentCash or cash equivalentIMLYGIC Biological, OncologyP1b2 talimogene laherparepvec + Yervoy combo melanoma2023
2023-04-26Regeneron Pharmaceuticals, Inc.$2,330Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-04-20Merck Sharp & Dohme LLC$7,136Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2023
2023-04-20Genentech, Inc.$1,350Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-04-20Genentech, Inc.$750Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-04-04PTC Therapeutics, Inc.$1,000Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2023
2023-04-01Boston Scientific Corporation$1,104Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023
2023-03-31Sterilmed, Inc.$424Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-03-29CSL Behring$156Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$65Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$54Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-29CSL Behring$39Research paymentIn-kind items and servicesA Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody2023
2023-03-23Genentech, Inc.$24,659Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-03-22ModernaTX, Inc.$500Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2023
2023-03-16Amylyx Pharmaceuticals, Inc.$28,798Research paymentCash or cash equivalentRELYVRIO Drug, NEUROLOGYPhase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix)2023
2023-03-08Regeneron Pharmaceuticals, Inc.$2,388Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-03-03Genentech, Inc.$12,505Research paymentCash or cash equivalentA study of balovaptan in acute ischemic stroke2023
2023-02-28Sterilmed, Inc.$287Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-02-23Genentech, Inc.$1,000Research paymentCash or cash equivalentA study of balovaptan in acute ischemic stroke2023
2023-02-22Regeneron Pharmaceuticals, Inc.$1,119Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-02-21Boston Scientific Corporation$1,698Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-02-13Genentech, Inc.$100Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-02-09Regeneron Pharmaceuticals, Inc.$1,119Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-02-03PTC Therapeutics, Inc.$1,000Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2023
2023-02-01Boston Scientific Corporation$1,104Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023
2023-02-01Boston Scientific Corporation$1,000Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023
2023-02-01Boston Scientific Corporation$500Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023
2023-01-31Sterilmed, Inc.$751Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-01-27Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-01-25Genentech, Inc.$3,500Research paymentCash or cash equivalentA study of balovaptan in acute ischemic stroke2023
2023-01-23Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2023
2023-01-20Regeneron Pharmaceuticals, Inc.$2,388Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-01-19Genentech, Inc.$24,907Research paymentCash or cash equivalentOcrevus Biological, ImmunologyA PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS2023
2023-01-18ModernaTX, Inc.$2,000Research paymentCash or cash equivalentA Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v2023
2023-01-18Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-01-17Boston Scientific Corporation$1,221Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN ICOPTION2023
2023-01-17Medtronic, Inc.$74Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2023
2023-01-06Regeneron Pharmaceuticals, Inc.$1,732Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2023
2023-01-03Medtronic, Inc.$2,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-01-03Medtronic, Inc.$1,500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-01-01Boston Scientific Corporation$756Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.0% in Oct 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.